文献速递中毒与环境急症消化、代谢与肾脏急症

马里兰州巴尔的摩市城市医疗中心急诊科有活跃阿片使用史患者中芬太尼暴露的患病率及其风险知识知晓情况

Prevalence of fentanyl exposure and knowledge regarding the risk of its use among emergency department patients with active opioid use history at an urban medical center in Baltimore, Maryland.
PubMed 文献 · Clin Toxicol (Phila) · 2019-09-01
一句话结论急诊有活跃阿片使用史患者尿检芬太尼暴露率高达80.6%,且三分之一非过量就诊者故意购买芬太尼,尽管多数知晓其高效价与致死风险。

该横断面研究于2018年5月20日至7月30日在马里兰州巴尔的摩市一家城市医院急诊科纳入165名有活跃阿片使用史(就诊前7天内使用阿片)的成人患者。采用快速尿液检测试纸检测芬太尼,并通过简要问卷收集人口学、物质使用史及芬太尼知识。129份尿液样本中104份(80.6%)检出芬太尼;84.2%识别芬太尼为高效价,85.5%知晓其过量死亡风险最高。非过量就诊组故意购买芬太尼的比例(34.1%)高于过量组(16.7%,p=0.04)。作者结论为多数有活跃阿片使用的急诊患者暴露于芬太尼,尽管知晓其效价和死亡高风险,仍有三分之一故意购买。

要点

  • 有活跃阿片使用史的急诊患者中,129份尿液样本104份(80.6%)检出芬太尼。
  • 165名参与者中42人(25.5%)因急性过量事件就诊急诊。
  • 84.2%(139人)认为芬太尼为高效价,85.5%(141人)知晓芬太尼过量死亡风险最高。
  • 非过量就诊者故意购买芬太尼的比例为34.1%(42人),高于过量就诊组的16.7%(7人),p=0.04。
  • 98.8%报告多物质使用,最常见为可卡因(57.6%,95人);海洛因是90.8%参与者的首选阿片,主要经鼻内途径(64.6%)。

适用人群与场景

  • 2018年5月20日至7月30日在马里兰州巴尔的摩市一家城市医院急诊科就诊的成人患者,有活跃阿片使用史(定义为就诊前7天内使用阿片)。
  • 研究期间451名患者报告活跃物质使用,其中208人报告活跃阿片使用,165人同意参与研究。
  • 参与者中位年龄49岁(四分位距38-57),77.0%(127人)为男性。

诊断标准与关键阈值

  • 活跃阿片使用定义为急诊就诊前7天内使用阿片。
  • 芬太尼暴露通过Rapid Response® Single Drug Test Strip(BTNX Inc.,Markham,Canada)检测尿液样本判定。

研究设计与关键结果

  • 横断面研究,165名有活跃阿片使用史的成人急诊患者纳入分析;42人(25.5%)因急性过量事件就诊。
  • 海洛因是90.8%参与者的首选阿片,主要经鼻内途径使用(64.6%);98.8%报告多物质使用,最常见为可卡因(57.6%,95人)。
  • 129份尿液样本中104份(80.6%)检出芬太尼。
  • 84.2%(139人)识别芬太尼为高效价,85.5%(141人)知晓芬太尼过量死亡风险最高。
  • 非过量就诊组故意购买芬太尼的比例为34.1%(42人),过量就诊组为16.7%(7人),p=0.04。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:多数有活跃阿片使用的急诊患者暴露于芬太尼;尽管知晓芬太尼效价和过量死亡高风险,仍有三分之一参与者故意购买芬太尼。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Overdose deaths from fentanyl and its analogs have increased significantly since 2013. There are limited data regarding the prevalence of fentanyl exposure among emergency department (ED) patients with active opioid use.Methods: We conducted a cross-sectional study at an urban hospital from May 20 to July 30, 2018. A convenience sample of adult ED patients with active opioid use, defined as opioid use within seven days prior to ED visit, were enrolled. Rapid Response® Single Drug Test Strip (BTNX Inc., Markham, Canada) was used to detect fentanyl in urine samples. Information on demographic, substance use history, and knowledge of fentanyl was obtained using a brief survey tool. Our primary outcome was the prevalence of fentanyl exposure; secondary outcomes included patients' knowledge regarding potency, risk of overdose death from fentanyl and intentional purchase of fentanyl.Results: During our study period, 451 patients reported active substance use. Of these, 208 reported active opioid use and 165 consented for the study. The median age was 49 years [interquartile range: 38, 57] and 77.0% (n = 127) were male; 42 participants (25.5%) presented to ED after an acute overdose event. Heroin was the preferred opioid of use in 90.8% of the participants, primarily via intranasal route (64.6%). Polysubstance use was reported in 98.8%, most commonly with cocaine (57.6%; n = 95). Fentanyl was detected in 104 out of 129 urine samples tested (80.6%). 84.2% (n = 139) identified fentanyl as highly potent and 85.5% (n = 141) recognized highest risk of death in fentanyl overdose. A larger proportion of non-overdose participants intentionally purchased fentanyl (34.1%; n = 42) compared to the overdose group (16.7%, n = 7; p = .04).Conclusions: The majority of ED patient with active opiate use were exposed to fentanyl while one in three participants intentionally purchased fentanyl despite their awareness of its potency and the high-risk of death from overdose.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Bach H, Jenkins V, Aledhaim A, et al. Prevalence of fentanyl exposure and knowledge regarding the risk of its use among emergency department patients with active opioid use history at an urban medical center in Baltimore, Maryland. Clin Toxicol (Phila). 2019. PMID: 31475588. doi:10.1080/15563650.2019.1657583

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。